'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Biocon has declined 3.35% to Rs 3821.4 crore. Sales of Generics segment has gone down 2.42% to Rs 686.40 crore (accounting for 17.51% of total sales). Sales of Biosimilars segment has gone down 7.81% to Rs 2,289.00 crore (accounting for 58.41% of total sales). Sales of Research service segment has gone up 10.57% to Rs 943.70 crore (accounting for 24.08% of total sales). Inter-segment sales rose Rs 86.10 crore to Rs 97.70 crore.
Profit before interest, tax and other unallocable items (PBIT) has slumped 79.32% to Rs 168.00 crore. PBIT of Generics reported loss of Rs 13.50 crore compared to profit of Rs 49.50 crore. PBIT of Biosimilars segment fell 99.64% to Rs 0.70 crore (accounting for 0.42% of total PBIT). PBIT of Research se...
Pleaselogin & subscribe to view the full report.
More Reports
-
(01-Mar-2025)
Foseco India
OP up 17%
-
(28-Feb-2025)
Schaeffler India
Maintains double digit revenue growth and stable OPM
-
(28-Feb-2025)
Sanofi India
OP up 18.78%
-
(28-Feb-2025)
KSB
Net up 33% largely on higher sales, higher OI and lower taxation
|
|